1 results match your criteria: "Health Science Center MA419A[Affiliation]"
Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
Am J Manag Care
April 2009
Department of Pulmonary, Critical Care and Environmental Medicine, University of Missouri-Columbia, One Hospital Dr, Health Science Center MA419A, Columbia, MO 65212, USA.
Objective: To assess the incremental cost-effectiveness of inhaled medication use in chronic obstructive pulmonary disease (COPD).
Study Design: A Markov model was constructed to estimate the incremental quality-adjusted life-years (QALYs) gained of the alternative treatment arms used in the Towards a Revolution in COPD Health (TORCH) study (ie, salmeterol-fluticasone propionate combination [SFC], salmeterol, fluticasone, and placebo).
Methods: The cycle length for the model was set to 3 months, and the maximum time horizon was set to 3 years.